SNTA Related Analyst Ratings
-
UPDATE: BMO Capital Downgrades Synta Pharma. (SNTA) to Market Perform
-
Synta Pharma (SNTA) Sell-Off Related to R&D Pres. Resignation, Could Be Buying Opp
-
JMP Securities Starts Synta Pharma. (SNTA) at Market Perform
-
Brean Capital Starts Synta Pharma. (SNTA) at Buy, Sees Upcoming Catalysts for Ganetespib
-
Jefferies Sharply Raises Target on Synta Pharma (SNTA) After GALAXY Update
-
Synta Phara (SNTA) Recieves Favorable Feedback Regarding Phase 2 - Jefferies
-
Stifel Nicolaus Starts Synta Pharma. (SNTA) at Hold
-
Jefferies Maintains a 'Buy' on Synta Pharma. (SNTA); Still See Significant Upside
-
Jefferies Maintains Bullish View on Synta Pharma. (SNTA) on GALAXY Survival Data
-
Jefferies Maintains a 'Buy' on Synta Pharma. (SNTA); Market Reaction Excessive
-
Jefferies Sees Nearly 100% Upside in Synta Pharma. (SNTA)
-
BMO Capital Upgrades Synta Pharma. (SNTA) to Outperform
-
Jefferies Starts Synta Pharma. (SNTA) at Buy
-
Canaccord Genuity Reiterates a 'Buy' on Synta Pharma (SNTA); Ganetespid Update
-
Canaccord Genuity Reiterates a 'Buy' on Synta Pharma. (SNTA) Following Meeting with Management
-
Rodman & Renshaw Starts Synta Pharma. (SNTA) at Market Outperform
-
Canaccord Genuity Maintains a 'Buy' on Synta Pharma. (SNTA); Q3/11 Update
-
ThinkEquity Starts Synta Pharma (SNTA) at Buy
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform
-
Canaccord Genuity Maintains a 'Buy' on Synta Pharma (SNTA); Q1/11: G-pib Development in NSCLC Advances
-
Canaccord Genuity Reiterates a 'Buy' on Synta Pharmaceuticals (SYNA); Ganetespib Combo NSCLC Study to Commence
-
Barclays Maintains an 'Equalweight' on Synta Pharma. (SNTA); Early Ganetespib Activity Encouraging
-
Canaccord Genuity Upgrades Synta Pharma (SNTA) to Buy
-
Morgan Joseph Initiates Coverage on Synta Pharmaceuticals (SNTA) with a Buy; Excited About Synta's Hsp90 Inhibitor
-
Roth Capital Upgrades Synta Pharmaceuticals (SNTA) to Buy; Valuation Call
-
Roth Capital Downgrades Synta Pharmaceuticals (SNTA) to Hold
-
RBC Downgrades Synta Pharma (SNTA) to Sector Perform
-
Lazard Downgrades Synta Pharma (SNTA) to Hold
-
Wachovia Downgrades Synta Pharmaceuticals (SNTA) to Underperform; Sees Continued Pressure
-
Canaccord Adams Initiates Coverage on Several Life Sciences Stocks: ALTH, EXEL, MITI, NPSP, OSIP, ONXX, PARD, SGEN & SNTA
-
BofA Initiates Coverage on Synta Pharmaceuticals (SNTA)
-
Wachovia Initiates Coverage on Synta Pharmaceuticals (SNTA) with a Market Perform
-
Susquehanna Initiates Synta Pharmaceuticals (SNTA) with a Positive
-
Friedman Billings Initiates Coverage on Synta Pharmaceuticals (SNTA) with an Outperform
-
RBC Capital Initiates Coverage on Synta Pharmaceuticals (SNTA) with an Outperform
-
Rodman & Renshaw Starts Synta Pharmaceuticals (SNTA) at Market Outerform
-
Lazard Capital Markets Starts Synta Pharmaceuticals (SNTA) at Buy
-
Montgomery Starts Synta Pharma (SNTA) at Buy
-
Bear Stearns Starts Synta Pharma (SNTA) at Outperform
Back to SNTA Stock Lookup
